Cell Source, Inc. is a biotechnology company, which focuses on developing cell therapy treatments based on the management of immune tolerance. The company is headquartered in New York City, New York. The company went IPO on 2014-01-14. The firm is primarily focused on the development of immune system management technology (Veto Cell technology). Its lead prospective product is its Veto Cell immune system management technology. Its Veto Cell technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is in pre-clinical phase, and its data shows that it provides results in allogeneic (donor-derived) hematopoietic stem cell transplantation (HSCT) by allowing for haploidentical stem cell transplants under a mild conditioning regimen. Its product pipeline includes chimeric antigen receptor (CAR) T-cell therapies, which include VETO CAR-T (with or without HSCT) for B-cell malignancies, Veto Cell kidney transplants, VETO CAR-T for solid tumors, Veto Cell liver transplants, and Veto HSCT for non-malignant disorders. The firm's wholly owned subsidiary is Cell Source Limited (CSL).
CLCS stock price ended at $0.84 on viernes, after rising 10.53%
On the latest trading day Jan 16, 2026, the stock price of CLCS rose by 10.53%, climbing from $0.76 to $0.84. Throughout the session, the stock experienced a volatility of 30.26%, with prices fluctuating between a daily low of $0.76 and a high of $0.99. Alongside this price increase, trading volume also rose by 23.9K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 23.4K shares were traded, amounting to a market value of approximately $33.6M.
Señales Técnicas de CLCS
Resumen de Señales Técnicas
Señales de compra 5
Señales Neutras 0
Señales de venta 2
Strong Sell
Sell
Neutral
Buy
Strong Buy
CLCS actualmente presenta 5 señales de compra y 2 señales de venta. La acción ha estado en una tendencia alcista desde 12:00 AM, con un cambio total en el precio de 40% durante este período. En general, los indicadores técnicos apuntan a una perspectiva Buy para el mediano plazo.
Señales alcistas/bajistas para CLCS
Analizamos indicadores clave como medias móviles, RSI, MACD y volumen de negociación para generar señales alcistas y bajistas para CLCS. Estas perspectivas te ayudan a tomar decisiones de inversión más informadas.
Preguntas de seguimiento
Comment les indicateurs d'analyse technique s'appliquent-ils à CLCS ?
Quels sont les niveaux de retracement de Fibonacci pour CLCS ?
Quel est le RSI de Cell Source Inc ?
Quel est le prix de Cell Source Inc pour les 12 prochains mois ?